Compare Alcon AG (ALC) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Morgan Stanley — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Morgan Stanley trades at $218.03 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 10.7× Alcon AG's market cap, and Morgan Stanley pays the higher dividend (1.8%). Which is the better fit depends on your goals.
| ALC | MS | |
|---|---|---|
Market Cap | $32.69B | $350.22B |
Sector | Health | Financials |
52-Week High | $92.22 | $227.19 |
52-Week Low | $62.02 | $139.09 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Morgan Stanley (MS) trades at $218.07, down 1.81% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth from $57.6B in 2024 to $66.0B in 2025. The stock shows technical bullish signals with moving averages supporting upward momentum and key resistance at $224-227. Recent developments include leading Anthropic's upcoming IPO and expanding AI integration in wealth management platforms.
The outlook remains positive with analyst consensus at Buy (53.85%) and a $225.80 price target offering 3.5% upside. Strong net income margin expansion to 26.34% and ROE of 17.36% support valuation, though negative operating cash flow and high leverage (debt-to-asset ratio of 26.1) present execution risks in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
